Fibroblast Activation Protein-Targeted PET Imaging of Metastatic Castration-Resistant Prostate Cancer Compared With 68Ga-PSMA and 18F-FDG PET/CT.
Clin Nucl Med
; 47(1): e54-e55, 2022 Jan 01.
Article
em En
| MEDLINE
| ID: mdl-34392294
ABSTRACT
ABSTRACT Herein we present 2 mCRPC (metastatic castration-resistant prostate cancer) patients who underwent 68Ga-PSMA PET/CT for PSMA-targeted radioligand therapy eligibility. Prior studies have noted aggressive clinical behavior and poor prognosis associated with discordant FDG positivity and low PSMA expression. Accordingly, the patients also underwent 18F-FDG PET/CT, which revealed intratumoral heterogeneity. Therefore, an additional PET/CT targeting fibroblast activation proteins (FAPs) using 68Ga-FAPI-04 was performed to assess the potential for an FAP-targeted therapy. This report highlights the theranostic potential of FAP imaging in mCRPC, particularly in patients with heterogeneous tumor phenotypes.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Fluordesoxiglucose F18
/
Neoplasias de Próstata Resistentes à Castração
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article